Table 4 The prevalence of AECA and autoantibodies directed to specific antigens of ANCA
AECA and ANCA directed to specific antigens other than MPO | Number and percentage with ANCA specificity | ||
|---|---|---|---|
Patients with PTU-induced vasculitis | Patients with PTU-induced MPO-ANCA but without clinical vasculitis | P value | |
(n = 17) | (n = 11) | ||
AECA | 15 (88.2%) | 0 (0) | <0.001 |
PR3 | 5 (29.4%) | 1 (9.1%) | 0.380 |
HLE | 12 (70.6%) | 3 (27.3%) | 0.011 |
Lactoferrin | 14 (82.4%) | 5 (45.5%) | 0.010 |
Cathepsin G | 11 (64.7%) | 0 (0) | <0.001 |
BPI | 0 (0) | 1 (9.1%) | 0.209 |
Azurocidin | 12 (70.6%) | 1 (9.1%) | <0.001 |
Number of ANCA target antigens recognized | 3 (2–4) | 0 (0–2%) | <0.001 |